DOI QR코드

DOI QR Code

MMP3 in Comparison to CA 125, HE4 and the ROMA Algorithm in Differentiation of Ovarian Tumors

  • Cymbaluk-Ploska, Aneta (Department of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University) ;
  • Chudecka-Glaz, Anita (Department of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University) ;
  • Surowiec, Anna (Department of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University) ;
  • Pius-Sadowska, Ewa (General Pathology Department, Pomeranian Medical University) ;
  • Machalinski, Boguslaw (General Pathology Department, Pomeranian Medical University) ;
  • Menkiszak, Janusz (Department of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University)
  • Published : 2016.05.01

Abstract

Ovarian cancer is a highly malignant neoplasm with high mortality rates. Research to identify markers facilitating early detection has been pursued for many years. Currently, diagnosis is based on the CA 125 and HE4 markers, as well as the ROMA algorithm. The search continues for new proteins that meet the criteria of good markers A total of 90 patients were included in the present study, allocated into: group 1, ovarian cancer, with 29 patients; group 2, endometrial cysts, with 30s; and group 3, simple ovarian cysts, with 31. Following histopathological verification, the CA 125, HE4, and metalloproteinase 3 (MMP3) levels were determined and the ROMA algorithm was calculated for all patients. The mean concentrations of all determined proteins, CA 125, HE4, and MMP3, as well as the ROMA values, were significantly higher in group 1 (ovarian cancer) compared to group 3 (simple ovarian cysts). The highest significant differences for the CA 125 levels (p<0.000001) and ROMA (p<0.000001) values were observed in postmenopausal women. For HE4, statistical significance was at the level of p=0.00001 compared to p=0.002 for MMP3. For the differentiation between ovarian cancer and endometrial cysts, the respective AUC ratios were obtained for CA 125, HE4, and MMP3 levels, as well as the ROMA values ( 0,93 / 0,96 / 0,75 / 0,98). After removing the post-menopausal patients, the MMP3 AUC value for ovarian cancer vs. benign ovarian cysts increased to 0.814. For post-menopausal women, the MMP3 AUC value for ovarian cancer vs. endometrial cysts was 0.843. As suggested by the results above, both the CA 125 and HE4 markers, as well as the ROMA algorithm, meet the criteria of a good diagnostic test for ovarian cancer. MMP3 seems to meet the criteria of a good diagnostic test, particularly in postmenopausal women; however, it is not superior to the tests used to date.

Keywords

MMP3;ROMA algorithm;HE4;CA 125;ovarian cancer

References

  1. Balduyck M, Zerimech F, Gouyer V, et al (2000). Specific expression of matrix metalloproteinases 1, 3, 9 and 13 associated with invasiveness of breast cancer cells in vitro. Clin Exp Metastasis, 18, 171-8. https://doi.org/10.1023/A:1006762425323
  2. Bandiera E, Romani C, Specchia C, et al (2011). Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management. Cancer Epidemiol Biomarkers Prev, 20, 2496-506. https://doi.org/10.1158/1055-9965.EPI-11-0635
  3. Baruch RR, Melinscak H, Lo J, et al (2001). Altered matrix metalloproteinase expression associated with oncogene-mediated cellular transformation and metastasis formation. Cell Biol Int, 25, 411-20. https://doi.org/10.1006/cbir.2000.0647
  4. Bodey B, Bodey B, Jr., Siegel SE, et al (2001). Immunocytochemical detection of matrix metalloproteinase expression in prostate cancer. In Vivo, 15, 65-70.
  5. Chambers AF, Matrisian LM (1997). Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst, 89, 1260-70. https://doi.org/10.1093/jnci/89.17.1260
  6. Chen WT, Gao X, Han XD, et al (2014). HE4 as a serum biomarker for ROMA prediction and prognosis of epithelial ovarian cancer. Asian Pac J Cancer Prev, 15, 101-5. https://doi.org/10.7314/APJCP.2014.15.1.101
  7. Choi JW, Ahn SE, Rengaraj D, et al (2011). Matrix metalloproteinase 3 is a stromal marker for chicken ovarian cancer. Oncol Lett, 2, 1047-51. https://doi.org/10.3892/ol.2011.391
  8. Chudecka-Glaz AM (2015). ROMA, an algorithm for ovarian cancer. Clin Chim Acta, 440, 143-51. https://doi.org/10.1016/j.cca.2014.11.015
  9. Coticchia CM, Curatolo AS, Zurakowski D, et al (2011). Urinary MMP-2 and MMP-9 predict the presence of ovarian cancer in women with normal CA125 levels. Gynecol Oncol, 123, 295-300. https://doi.org/10.1016/j.ygyno.2011.07.034
  10. Folkman J, Cotran R (1976). Relation of vascular proliferation to tumor growth. Int Rev Exp Pathol, 16, 207-48.
  11. Fu Z, Xu S, Xu Y, et al (2015). The expression of tumor-derived and stromal-derived matrix metalloproteinase 2 predicted prognosis of ovarian cancer. Int J Gynecol Cancer, 25, 356-62. https://doi.org/10.1097/IGC.0000000000000386
  12. Kristjansdottir B, Levan K, Partheen K, et al (2013). Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer. Gynecol Oncol, 131, 52-8. https://doi.org/10.1016/j.ygyno.2013.07.094
  13. Li F, Tie R, Chang K, et al (2012). Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and CA125 in predicting epithelial ovarian cancer: a meta-analysis. BMC Cancer, 12, 258. https://doi.org/10.1186/1471-2407-12-258
  14. Li Y, Jin X, Kang S, et al (2006). Polymorphisms in the promoter regions of the matrix metalloproteinases-1, -3, -7, and -9 and the risk of epithelial ovarian cancer in China. Gynecol Oncol, 101, 92-6. https://doi.org/10.1016/j.ygyno.2005.09.058
  15. Menon R, Fortunato SJ (2004). The role of matrix degrading enzymes and apoptosis in rupture of membranes. J Soc Gynecol Investig, 11, 427-37. https://doi.org/10.1016/j.jsgi.2004.04.001
  16. Molina R, Escudero JM, Auge JM, et al (2011). HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases. Tumour Biol, 32, 1087-95. https://doi.org/10.1007/s13277-011-0204-3
  17. Muyldermans M, Cornillie FJ, Koninckx PR (1995). CA125 and endometriosis. Hum Reprod Update, 1, 173-87. https://doi.org/10.1093/humupd/1.2.173
  18. Ortiz-Munoz B, Aznar-Oroval E, Garcia Garcia A, et al (2014). HE4, Ca125 and ROMA algorithm for differential diagnosis between benign gynaecological diseases and ovarian cancer. Tumour Biol, 35, 7249-58. https://doi.org/10.1007/s13277-014-1945-6
  19. Partheen K, Kristjansdottir B, Sundfeldt K (2011). Evaluation of ovarian cancer biomarkers HE4 and CA-125 in women presenting with a suspicious cystic ovarian mass. J Gynecol Oncol, 22, 244-52. https://doi.org/10.3802/jgo.2011.22.4.244
  20. Sheu BC, Lien HC, Ho HN, et al (2003). Increased expression and activation of gelatinolytic matrix metalloproteinases is associated with the progression and recurrence of human cervical cancer. Cancer Res, 63, 6537-42.
  21. Smolarz B, Szyllo K, Romanowicz-Makowska H, et al (2003). PCR analysis of matrix metalloproteinase 3 (MMP-3) gene promoter polymorphism in ovarian cancer. Pol J Pathol, 54, 233-8.
  22. Sun N, Zhang Q, Xu C, et al (2014). Molecular regulation of ovarian cancer cell invasion. Tumour Biol, 35, 11359-66. https://doi.org/10.1007/s13277-014-2434-7
  23. Winarto H, Laihad BJ, Nuranna L (2014). Modification of cutoff values for HE4, CA125, the Risk of Malignancy Index, and the Risk of Malignancy Algorithm for ovarian cancer detection in Jakarta, Indonesia. Asian Pac J Cancer Prev, 15, 1949-53. https://doi.org/10.7314/APJCP.2014.15.5.1949